Dipeptidyl peptidase-4

Dipeptidyl Peptidase-4 (DPP-4) is an enzyme encoded by the DPP4 gene in humans. DPP-4 plays a significant role in glucose metabolism by inactivating incretin hormones, which are involved in the physiological regulation of glucose homeostasis. Inhibitors of DPP-4 are used in the treatment of Type 2 diabetes because of their ability to increase incretin levels, which inhibit glucagon release, thereby increasing insulin secretion, decreasing gastric emptying, and reducing blood glucose levels.

Function

DPP-4 is a serine exopeptidase that cleaves X-proline dipeptides from the N-terminus of polypeptides. Its substrates include incretin hormones such as Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP), which are secreted by intestinal cells in response to meals and enhance insulin secretion from the pancreas. By inactivating these hormones, DPP-4 regulates the effect of incretins on insulin and glucagon secretion.

Clinical Significance

The inhibition of DPP-4 has become a therapeutic strategy in the management of Type 2 diabetes, aiming to increase the levels of active incretin hormones, improve beta-cell function, and subsequently improve glycemic control. DPP-4 inhibitors, also known as gliptins, are a class of oral hypoglycemics that block the enzyme's action, thus prolonging the action of incretin hormones.

DPP-4 Inhibitors

Several DPP-4 inhibitors have been approved for use, including Sitagliptin, Vildagliptin, Saxagliptin, and Linagliptin. These medications are generally well-tolerated and can be used alone or in combination with other antidiabetic drugs.

Associated Conditions

Beyond diabetes, research has explored the role of DPP-4 in various conditions, suggesting its involvement in immune regulation, inflammation, and possibly influencing cardiovascular health. Elevated DPP-4 activity has been observed in various diseases, indicating its potential as a biomarker or therapeutic target beyond diabetes.

Safety and Efficacy

DPP-4 inhibitors have been shown to be effective in lowering blood glucose levels with a low risk of hypoglycemia and without causing significant weight gain. However, they are associated with specific adverse effects, such as a risk of pancreatitis and potential joint pain. Ongoing research aims to further elucidate the long-term cardiovascular outcomes associated with their use.

Conclusion

DPP-4 and its inhibitors represent a crucial aspect of modern Type 2 diabetes management, with ongoing research into their broader implications for health and disease. As understanding of this enzyme continues to evolve, so too will its therapeutic potential.